 Gain Therapeutics Inc NASDAQ: GANX are trading higher Wednesday after the company announced positive topline data in a patient-derived iPSC study evaluating STAR compounds as a treatment for Gaucher and Parkinsons disease. Gain Therapeutics identified the two lead STAR candidates through its proprietary SEE-Tx platform. 